KCNN4 and cystic fibrosis: The potential use of KCa3.1 inhibitors corresponds with what has been called a “mutation-agnostic” treatment that might be used specially in patients with CF that are not eligible for the new available therapies, and it also seems suitable for easing other muco-obstructive diseases affecting humans.